Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 7 clients • 18 examiners • 10 art units • 0 of 19 (0%) have an AI response strategy ready
Dentons Cohen & Grigsby P.C. is a patent law firm with 29855 career applications. The firm focuses on Biotechnology & Pharmaceuticals. It has achieved a resolved allowance rate pct of 88.66. This success is supported by an avg office actions per allowance of 3.32. Currently, the firm has 17 pending office actions.
The avg office actions per allowance of 3.32 indicates a prosecution style involving several rounds of examiner interaction. This approach has resulted in a resolved allowance rate pct of 88.66 across 29855 career applications. The 17 pending office actions represent a fraction of the firm's total historical volume, suggesting a resolved docket. For practitioners, these metrics provide a picture of the firm's ability to navigate technical fields and secure patent grants consistently. The firm's 29855 career applications establish its long-term presence in Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 3 (16%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 14 (74%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 2 | 68.0% | +55.6% |
| HARTMANN, GARY S | 1 | 72.7% | +18.9% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| BUI, LUAN KIM | 1 | 69.0% | +28.4% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| BERA, HENA RAKESHKUMAR | 1 | — | — |
| GROOMS, NOA WILLIAM FRAN | 1 | 75.0% | +0.0% |
| VANNI, GEORGE STEVEN | 1 | 67.4% | +24.4% |
| WEINER, LAURA S | 1 | 85.3% | +14.3% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17494690 | MODULATING ISCHEMIC INJURY | CLARKE, TRENT R | 141d overdue |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | JOHANSEN, PETER N. | 30d overdue |
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | BUI, LUAN KIM | 13d |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | BUTTICE, AUDREY L | 33d |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | VANNI, GEORGE STEVEN | 84d |
| 18969554 | MOBILE ROAD SURFACE TREATMENT SYSTEM | HARTMANN, GARY S | — |
| 18696453 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | DICKINSON, PAUL W | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | SAMALA, JAGADISHWAR RAO | 58d overdue |
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | BUI, LUAN KIM | 13d |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | VANNI, GEORGE STEVEN | 84d |
| 18969554 | MOBILE ROAD SURFACE TREATMENT SYSTEM | HARTMANN, GARY S | — |
| 18887845 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | CRAIG, KAILA ANGELIQUE | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18369331 | ELECTRODE SURFACE ENGINEERING IN LITHIUM ION BATTERIES | WEINER, LAURA S | — |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | — |
| Client (Assignee) | Pending OAs |
|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | 12 |
| Carnegie Mellon University | 2 |
| Silly Surfacing, LLC | 1 |
| Roesler IP GmbH | 1 |
| Horizon Technology | 1 |
| Signature Diagnostics Inc. | 1 |
| NOVEOME BIOTHERAPEUTICS, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1618 | 5 |
| 3736 | 1 |
| 2877 | 1 |
| 1686 | 1 |
| 1723 | 1 |
| 1614 | 1 |
| 1646 | 1 |
| 1651 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18969554 | MOBILE ROAD SURFACE TREATMENT SYSTEM | Silly Surfacing, LLC | HARTMANN, GARY S | §102§103 | Non-Final OA | — | Pending | Dec 05, 2024 | |
| 18887845 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | Actinium Pharmaceuticals, Inc. | CRAIG, KAILA ANGELIQUE | §103 | Non-Final OA | — | Pending | Sep 17, 2024 | |
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | Roesler Ip GmbH | BUI, LUAN KIM | 3736 | §102§103§112 | Non-Final OA | 13d | Pending | Sep 12, 2024 |
| 18696453 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | DICKINSON, PAUL W | §102§112 | Non-Final OA | — | Pending | Mar 28, 2024 | |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | SAMALA, JAGADISHWAR RAO | §102§103 | Non-Final OA | — | Pending | Feb 15, 2024 | |
| 18441844 | REACTIVE CONDENSATION PARTICLE COUNTER FOR THE DETECTION OF TRACE ATMOSPHERIC GASES | Carnegie Mellon University | BERA, HENA RAKESHKUMAR | 2877 | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18292413 | MAGNETIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Horizon Technology | GROOMS, NOA WILLIAM FRAN | §103§112 | Non-Final OA | — | Pending | Jan 26, 2024 | |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | Signature Diagnostics Inc. | VANNI, GEORGE STEVEN | 1686 | §101§112 | Non-Final OA | 84d | Pending | Nov 20, 2023 |
| 18369331 | ELECTRODE SURFACE ENGINEERING IN LITHIUM ION BATTERIES | Carnegie Mellon University | WEINER, LAURA S | 1723 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | Actinium Pharmaceuticals, Inc. | SCHLIENTZ, LEAH H | 1618 | §102§103 | Non-Final OA | — | Pending | May 12, 2023 |
| 17726296 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Non-Final OA | — | Pending | Apr 21, 2022 |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | CABRAL, ROBERT S | 1614 | §103§112DP | Non-Final OA | — | Pending | Apr 20, 2022 |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Final Rejection | 35d overdue | Pending | Mar 23, 2022 |
| 17606226 | COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES | Actinium Pharmaceuticals, Inc. | WESTERBERG, NISSA M | 1618 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 17494690 | MODULATING ISCHEMIC INJURY | Noveome Biotherapeutics, Inc. | CLARKE, TRENT R | 1651 | §102§103§112Other | Final Rejection | 141d overdue | Pending | Oct 05, 2021 |
| 17293663 | COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNE CHECKPOINT THERAPY IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | VU, JAKE MINH | 1618 | §102§103§112Other | Non-Final OA | — | Pending | May 13, 2021 |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | Actinium Pharmaceuticals, Inc. | JOHANSEN, PETER N. | 1644 | §103§112 | Non-Final OA | 30d overdue | Pending | Apr 12, 2020 |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | Actinium Pharmaceuticals, Inc. | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 33d | Pending | Apr 08, 2020 |
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | Actinium Pharmaceuticals, Inc. | SAMALA, JAGADISHWAR RAO | 1618 | §103 | Final Rejection | 58d overdue | Pending | Dec 31, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial